Applied Filters
CRISPR: A licence to heal
As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood.
Brexit: The waiting game
As lawyers and industry prepare for a possible no-deal Brexit, the uncertainty surrounding its impact runs like a core through the industry, as LSIPR’s Saman Javed discovers.
IP portfolios: the five biggest headaches for in-house counsel
In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.
Genetic research: DNA payday
A tie-up between four leading pharmaceutical companies, the UK government and a health charity has created the world’s largest genetic research project. LSIPR’s Rory O’Neill looks at a new frontier for life sciences.
CRISPR: Hearing all about it
There is no doubting the importance of next year’s CRISPR appeal, but any conclusions about the parties’ prior art have consequences for elsewhere too, say Catherine Coombes and Emma Longland of HGF.
The future of precision medicine part 7: public engagement
For all the importance of the role of government and private sector bodies in the realisation of precision medicine, it’s important not to lose sight of the interests and concerns of those precision medicine intends to treat—the patients and public at large, write Daniel Lim and Anna Jackson of Kirkland & Ellis.
The future of precision medicine part 4: diagnosing the diagnostic problem
The development of precision treatments must be complemented by the development of precision diagnostics, as Daniel Lim of Kirkland & Ellis explains.
The future of precision medicine part 3: translation from research to the clinic
The implementation of precision medicine represents a huge, possibly unprecedented, challenge to conventional clinical practice across the breadth of healthcare disciplines, says Daniel Lim of Kirkland & Ellis.
Gene-editing: a block on further development
An EU court ruling on gene-editing regulation has sparked widespread concerns in the scientific and legal communities, as LSIPR finds out.
How the EPO treats personalised healthcare patents
The patenting of personalised healthcare inventions has proved problematic in a number of jurisdictions, but various aspects of these inventions are patentable in Europe, as Laurence Gainey of HGF explains.
